Skip to main content
Erschienen in: Supportive Care in Cancer 12/2020

23.03.2020 | Original Article

Do patients enrolled in observational studies have better outcomes than non-participants? A retrospective analysis

verfasst von: Gina Wong, Emily Lam, Edward Chow, Liying Zhang, Chun Nim Li, Gord Mawdsley, Irene Karam, Krista Ariello, Victoria McCarvell, Yasmeen Razvi, Mark Ruschin

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients are commonly enrolled into clinical trials. It has been reported that these patients may have better outcomes than those not enrolled into the study. The reasoning from these improvements could be attributable to closer follow-up, better patient adherence, more health aware patients have, or reaction to observation such as the Hawthorne effect.

Methods

Three hundred forty-six patients were approached for a prospective skin toxicity study in adjuvant breast cancer radiotherapy (RT) but declined participation between January 2018 and July 2019 (non-trial group). They were retrospectively reviewed and patient, treatment and RT-related characteristics, as well as the occurrence of skin reactions, and the usage of topical treatments were collected. This was compared with a comparison cohort of 349 patients who were enrolled into a previously conducted prospective study (trial group).

Results

More patients in the trial group had conventional RT (CFRT) versus hypofractionated RT (HFRT). Data was further stratified and there was no significant difference in moist desquamation, topical antibiotic usage, dressing application, home care use, topical corticoid steroid use, and oral analgesic use. There was a significantly lower pain score in the group compared with the non-trial group in both HFRT and CFRT (OR = 0.091 and OR = 0.348, p < 0.0001).

Conclusion

Our results demonstrated no differences other than pain between the trial group and non-trial group. Therefore, in this cohort, patients enrolled into an observational trial while undergoing adjuvant breast RT demonstrated similar experiences of skin reactions. There are challenges to assessing differences between these groups, as confounding is likely. Therefore, it is recommended for future studies to additionally assess the impact of study participation on outcomes such as quality of life, quality of care received, and/or anxiety levels.
Literatur
1.
Zurück zum Zitat Canadian Cancer Clinical Trials Network. Participation in Clinical Trials in Ontario | Canadian Cancer Clinical Trials Network. 2018 Canadian Cancer Clinical Trials Network. Participation in Clinical Trials in Ontario | Canadian Cancer Clinical Trials Network. 2018
2.
Zurück zum Zitat Downing A, Morris EJ, Corrigan N, Sebag-Montefiore D, Finan PJ, Thomas JD, Chapman M, Hamilton R, Campbell H, Cameron D, Kaplan R, Parmar M, Stephens R, Seymour M, Gregory W, Selby P (2017) High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut. 66(1):89–96CrossRef Downing A, Morris EJ, Corrigan N, Sebag-Montefiore D, Finan PJ, Thomas JD, Chapman M, Hamilton R, Campbell H, Cameron D, Kaplan R, Parmar M, Stephens R, Seymour M, Gregory W, Selby P (2017) High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut. 66(1):89–96CrossRef
3.
Zurück zum Zitat Bois A Du, Rochon J, Lamparter C, PFisterer J, AGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 2005;15(2):183–191 Bois A Du, Rochon J, Lamparter C, PFisterer J, AGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 2005;15(2):183–191
4.
Zurück zum Zitat McCambridge J, Witton J, Elbourne DR (2014) Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 67(3):267–277CrossRef McCambridge J, Witton J, Elbourne DR (2014) Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 67(3):267–277CrossRef
5.
Zurück zum Zitat Gale EAM (2004) The Hawthorne studies--a fable for our times? QJM. 97(7):439–449CrossRef Gale EAM (2004) The Hawthorne studies--a fable for our times? QJM. 97(7):439–449CrossRef
6.
Zurück zum Zitat Drost L, Li N, Vesprini D, Sangha A, Lee J, Leung E, Rakovitch E, Yee C, Chow E, Ruschin M (2018) Prospective study of breast radiation dermatitis. Clin Breast Cancer 18(5):e789–e795CrossRef Drost L, Li N, Vesprini D, Sangha A, Lee J, Leung E, Rakovitch E, Yee C, Chow E, Ruschin M (2018) Prospective study of breast radiation dermatitis. Clin Breast Cancer 18(5):e789–e795CrossRef
7.
Zurück zum Zitat Harper JL, Franklin LE, Jenrette JM, Aguero EG (2004) Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97(10):989–993CrossRef Harper JL, Franklin LE, Jenrette JM, Aguero EG (2004) Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97(10):989–993CrossRef
8.
Zurück zum Zitat Kole AJ, Kole L, Moran MS (2017) Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer Targets Ther 9:313–323CrossRef Kole AJ, Kole L, Moran MS (2017) Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer Targets Ther 9:313–323CrossRef
9.
Zurück zum Zitat Chan S, Sutradhar R, Yao Z et al (2019) Fractionation in adjuvant radiotherapy for invasive breast cancer and ductal carcinoma in situ in Ontario, Canada from 2009 to 2015. Breast J, September Chan S, Sutradhar R, Yao Z et al (2019) Fractionation in adjuvant radiotherapy for invasive breast cancer and ductal carcinoma in situ in Ontario, Canada from 2009 to 2015. Breast J, September
10.
Zurück zum Zitat Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol • Biol • Phys. 2014;90(5):1001–1009 Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol • Biol • Phys. 2014;90(5):1001–1009
11.
Zurück zum Zitat Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ (2014) Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA. 312(23):2542–2550CrossRef Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ (2014) Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA. 312(23):2542–2550CrossRef
12.
Zurück zum Zitat Parekh A, Dholakia AD, Zabranksy DJ, Asrari F, Camp M, Habibi M, Zellars R, Wright JL (2018) Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: role of fractionation and treatment volume. Adv Radiat Oncol 3(1):8–15CrossRef Parekh A, Dholakia AD, Zabranksy DJ, Asrari F, Camp M, Habibi M, Zellars R, Wright JL (2018) Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: role of fractionation and treatment volume. Adv Radiat Oncol 3(1):8–15CrossRef
13.
Zurück zum Zitat Tortorelli G, Di Murro L, Barbarino R et al (2013) Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. BMC Cancer 13(1):230CrossRef Tortorelli G, Di Murro L, Barbarino R et al (2013) Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. BMC Cancer 13(1):230CrossRef
14.
Zurück zum Zitat Zhou Z-R, Mei X, Chen X-X, Yang ZZ, Hou J, Zhang L, Yu XL, Guo XM (2015) Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. Surg Oncol 24(3):200–211CrossRef Zhou Z-R, Mei X, Chen X-X, Yang ZZ, Hou J, Zhang L, Yu XL, Guo XM (2015) Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. Surg Oncol 24(3):200–211CrossRef
15.
Zurück zum Zitat O’Sullivan I, Orbell S, Rakow T, Parker R (2004) Prospective research in health service settings: health psychology, science and the “Hawthorne” effect. J Health Psychol 9(3):355–359CrossRef O’Sullivan I, Orbell S, Rakow T, Parker R (2004) Prospective research in health service settings: health psychology, science and the “Hawthorne” effect. J Health Psychol 9(3):355–359CrossRef
16.
Zurück zum Zitat De Amici D, Klersy C, Ramajoli F, Brustia L, Politi P (2000) Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Control Clin Trials 21(2):103–114CrossRef De Amici D, Klersy C, Ramajoli F, Brustia L, Politi P (2000) Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Control Clin Trials 21(2):103–114CrossRef
17.
Zurück zum Zitat McCarney R, Warner J, Iliffe S, Van Haselen R, Griffin M, Fisher P (2007) The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol 7 McCarney R, Warner J, Iliffe S, Van Haselen R, Griffin M, Fisher P (2007) The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol 7
18.
Zurück zum Zitat Wickström G, Bendix T (2000) The &quot;Hawthorne effect&quot;-what did the original Hawthorne studies actually show? Scand J Work Environ Health 26(4):363–367CrossRef Wickström G, Bendix T (2000) The &quot;Hawthorne effect&quot;-what did the original Hawthorne studies actually show? Scand J Work Environ Health 26(4):363–367CrossRef
19.
Zurück zum Zitat Greenwood R, Bolton A, Greenwood R (1983) Hawthorne a half century later: relay assembly participants remember. J Manage 9(2):217–231 Greenwood R, Bolton A, Greenwood R (1983) Hawthorne a half century later: relay assembly participants remember. J Manage 9(2):217–231
20.
Zurück zum Zitat Greenberg RA, Wagner EH, Wolf SH, Cohen SB, Kleinbaum DG, Williams CA, Ibrahim MA (1978) Physician opinions on the use of antibiotics in respiratory infections. JAMA. 240(7):650–653CrossRef Greenberg RA, Wagner EH, Wolf SH, Cohen SB, Kleinbaum DG, Williams CA, Ibrahim MA (1978) Physician opinions on the use of antibiotics in respiratory infections. JAMA. 240(7):650–653CrossRef
Metadaten
Titel
Do patients enrolled in observational studies have better outcomes than non-participants? A retrospective analysis
verfasst von
Gina Wong
Emily Lam
Edward Chow
Liying Zhang
Chun Nim Li
Gord Mawdsley
Irene Karam
Krista Ariello
Victoria McCarvell
Yasmeen Razvi
Mark Ruschin
Publikationsdatum
23.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05417-w

Weitere Artikel der Ausgabe 12/2020

Supportive Care in Cancer 12/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.